Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866414 | 0.84 | EPHX1 (0.57) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL7747186 | 0.84 | NPC1 (0.64) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL16364130 | 0.81 | HDAC3 (0.56) | NPC1RAB9ASMN1; SMN2MEN1TP53 | |
| SCHEMBL24894195 | 0.81 | ALDH1A1 (0.58) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL19252045 | 0.80 | MEN1 (0.66) | RAB9AMEN1KMT2ACNR1MAPT | |
| SCHEMBL18897610 | 0.80 | RAB9A (0.46) | NPC1RAB9ASMN1; SMN2MEN1HPGD | |
| SCHEMBL3865302 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MEN1HPGD | |
| SCHEMBL5851707 | 0.79 | NPC1 (0.68) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL23135816 | 0.79 | MAPT (0.51) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL1275920 | 0.78 | ALDH1A1 (0.70) | NPC1RAB9APOLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745982-B | Oxadiazole compound and preparation method and application thereof | 中国药科大学 | 2024-09-17 | — | — | CN | disclosed |
| CN-115745982-A | Oxadiazole compound and preparation method and application thereof | 中国药科大学 | 2023-03-07 | — | — | CN | disclosed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1873159-A1 | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007147575-A2 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISINGS SAME, METHODS OF PREPARING SAME AND USES SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | NPC1 4377/4885RAB9A 4586/4885POLB 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.